Gland Pharma · NSE: GLAND · BSE: 543245
Q2 FY22 results · Jul–Sep 2021
Gland Pharma reported revenue from operations of ₹1,080.47 crore and net profit of ₹302.08 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,080.47 | — | — | 1,153.90 | −6.4% |
| Other income | 51.20 | — | — | 61.84 | −17.2% |
| Total income | 1,131.67 | — | — | 1,215.74 | −6.9% |
| Profit before tax | 400.67 | — | — | 471.84 | −15.1% |
| Net profit for the period | 302.08 | — | — | 350.65 | −13.9% |
| EPS, basic (₹) | 18.37 | — | — | 21.41 | −14.2% |
| Net margin (%) | 28.0 | — | 30.4 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,080.47 | — | — | 1,153.90 | −6.4% |
| Other income | 51.20 | — | — | 61.84 | −17.2% |
| Total income | 1,131.67 | — | — | 1,215.74 | −6.9% |
| Profit before tax | 400.70 | — | — | 471.86 | −15.1% |
| Net profit for the period | 302.12 | — | — | 350.68 | −13.8% |
| EPS, basic (₹) | 18.37 | — | — | 21.41 | −14.2% |
| Net margin (%) | 28.0 | — | 30.4 |
Consolidated
- Filed with BSE
- 23 Oct 2021, 14:04 IST
- Board meeting
- 22 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Oct 2021, 14:04 IST
- Board meeting
- 22 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE